EGFR mutation analysis and treatment outcomes with tyrosine kinase inhibitors in EGFR mutants: The Manchester Lung Cancer Group Experience.

R Peck; E Connolly; P Taylor; C Faivre-Finn; FH Blackhall; A Wallace; L Lee; N Bayman; P Burt; YJ Summers

EGFR mutation analysis and treatment outcomes with tyrosine kinase inhibitors in EGFR mutants: The Manchester Lung Cancer Group Experience.

R Peck, E Connolly, P Taylor, C Faivre-Finn, FH Blackhall, A Wallace, L Lee, N Bayman, P Burt, YJ Summers

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	30
Issue number	15
Publication status	Published - 20 May 2012

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{28249e3f2ee74cedba4d9b8949c5393c,

title = "EGFR mutation analysis and treatment outcomes with tyrosine kinase inhibitors in EGFR mutants: The Manchester Lung Cancer Group Experience.",

author = "R Peck and E Connolly and P Taylor and C Faivre-Finn and FH Blackhall and A Wallace and L Lee and N Bayman and P Burt and YJ Summers",

year = "2012",

month = may,

day = "20",

language = "English",

volume = "30",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins",

number = "15",

}

TY - JOUR

T1 - EGFR mutation analysis and treatment outcomes with tyrosine kinase inhibitors in EGFR mutants

T2 - The Manchester Lung Cancer Group Experience.

AU - Peck, R

AU - Connolly, E

AU - Taylor, P

AU - Faivre-Finn, C

AU - Blackhall, FH

AU - Wallace, A

AU - Lee, L

AU - Bayman, N

AU - Burt, P

AU - Summers, YJ

PY - 2012/5/20

Y1 - 2012/5/20

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000318009804155&DestLinkType=FullRecord&DestApp=WOS

M3 - Meeting Abstract

SN - 0732-183X

VL - 30

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15

ER -

EGFR mutation analysis and treatment outcomes with tyrosine kinase inhibitors in EGFR mutants: The Manchester Lung Cancer Group Experience.

Research Beacons, Institutes and Platforms

UN SDGs

Other files and links

Cite this